Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD --(L)1 refractory/resistant unresectable or metastatic melanoma from a Phase 1b study

 PDF   14   05/2021

Clinical presentation by Cheng Chen, M.D.

Rating

Rate this resource

Nice to see you!

For newest details on our EHA materials in a personal video meeting, please click here!
Service